Erhan Gökmen

8.1k total citations · 1 hit paper
56 papers, 3.4k citations indexed

About

Erhan Gökmen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Erhan Gökmen has authored 56 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Erhan Gökmen's work include Cancer Immunotherapy and Biomarkers (13 papers), Cancer Treatment and Pharmacology (11 papers) and Advanced Breast Cancer Therapies (10 papers). Erhan Gökmen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Cancer Treatment and Pharmacology (11 papers) and Advanced Breast Cancer Therapies (10 papers). Erhan Gökmen collaborates with scholars based in Türkiye, United States and Australia. Erhan Gökmen's co-authors include Piotr Tomczak, Robert J. Motzer, Vladimir Lesovoy, Janice Dutcher, Gary R. Hudes, Robert A. Figlin, Ingo G.H. Schmidt‐Wolf, Anil Kapoor, I. Bodrogi and Elżbieta Starosławska and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Erhan Gökmen

43 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

2007 2.8k citations Piotr Tomczak, Erhan Gökmen et al. profile →

Peers

Erhan Gökmen

PRM

ONCOL

SURGE

Janice Dutcher United States

David McDermott United States

Zoran Kovačević Serbia

Oleg Gladkov Russia

Norbert Hollaender Switzerland

Ana M. Molina United States

N. Moore Switzerland

Gladys Urbanowitz United States

Debasish Roychowdhury United States

James R. Vasselli United States

Janice Dutcher United States

Erhan Gökmen

2.6k ×1.1

PRM

2.4k ×1.1

1.4k ×1.1

1.1k ×1.0

ONCOL

276 ×1.0

SURGE

Citations per year, relative to Erhan Gökmen Erhan Gökmen (= 1×) peers Janice Dutcher

Countries citing papers authored by Erhan Gökmen

Since Specialization

Citations

This map shows the geographic impact of Erhan Gökmen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erhan Gökmen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erhan Gökmen more than expected).

Fields of papers citing papers by Erhan Gökmen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erhan Gökmen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erhan Gökmen. The network helps show where Erhan Gökmen may publish in the future.

Co-authorship network of co-authors of Erhan Gökmen

This figure shows the co-authorship network connecting the top 25 collaborators of Erhan Gökmen. A scholar is included among the top collaborators of Erhan Gökmen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erhan Gökmen. Erhan Gökmen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Voss, Martin H., Howard Gurney, Vagif Atduev, et al.. (2025). First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. European Urology. 88(6). 614–624.

Başaran, Gül, Erhan Gökmen, Nil Molinas Mandel, et al.. (2024). Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases.. Journal of Clinical Oncology. 42(16_suppl). 545–545.

Aksoy, Sercan, Burcu Çakar, Gül Başaran, et al.. (2023). Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group. Cancers. 15(6). 1667–1667. 1 indexed citations

Cescon, David W., Peter Schmid, Hope S. Rugo, et al.. (2023). Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. JNCI Journal of the National Cancer Institute. 116(5). 717–727. 7 indexed citations

Albigès, Laurence, Howard Gurney, Vagif Atduev, et al.. (2023). Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. The Lancet Oncology. 24(8). 881–891. 73 indexed citations

Cescon, David W., H. S. Rugo, S-A. Im, et al.. (2022). 164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355. Annals of Oncology. 33. S197–S198. 2 indexed citations

Şendur, Mehmet Alı Nahıt, Burcu Çakar, Sercan Aksoy, et al.. (2021). 124P Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey. Annals of Oncology. 32. S74–S74. 1 indexed citations

Cortés, Javier, David W. Cescon, Hope S. Rugo, et al.. (2021). LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Annals of Oncology. 32. S1289–S1290. 37 indexed citations

Önay, Hüseyin, Levent Yenıay, Erhan Gökmen, et al.. (2020). BRCA1-BRCA2 mutation analysis results in 910 individuals: Mutation distribution and 8 novel mutations. Cancer Genetics. 241. 20–24. 4 indexed citations

10.

Haydaroğlu, Ayfer, Burcu Çakar, Erhan Gökmen, et al.. (2019). Ege Üniversitesi Hastanesi veri tabanında meme kanseri hastalarının epidemiyolojisi ve genel sağ kalım özellikleri. Ege Tıp Dergisi. 50–57.

11.

Çakar, Burcu, Erhan Gökmen, Banu Sarsık, et al.. (2019). Ege Üniversitesi Hastanesinde testis kanserlerinin epidemiyolojisi ve genel sağ kalım özellikleri. Ege Tıp Dergisi. 126–132. 1 indexed citations

12.

Pehlivanoğlu, Burçin, et al.. (2017). Comparison of HER2 status determination methods in HER2 (2 +) patients: Manual fluorescent in situ hybridization (FISH) vs. dual silver enhanced in situ hybridization (SISH). Annals of Diagnostic Pathology. 31. 36–40. 2 indexed citations

13.

Mete, Nihal, Dilek Akkuş, Nazan Özsan, et al.. (2014). Frontal Lobe Like Syndrome Due To Bee Sting. 31(2). 398–407. 3 indexed citations

14.

Rordorf, Tamara, Ibrahim A. Hassan, Hamdy A. Azim, et al.. (2014). Bone health in breast cancer patients: A comprehensive statement by CECOG/SAKK Intergroup. The Breast. 23(5). 511–525. 14 indexed citations

15.

Sarsık, Banu, et al.. (2009). Böbrekte kitle nedeniyle yapılan iğne kor biyopsileri ve tanı zorlukları. Turkish Journal of Pathology. 25(1). 5–18.

16.

Sezgin, Canfeza, et al.. (2007). Risk factors for central nervous system metastasis in patients with metastatic breast cancer. Medical Oncology. 24(2). 155–161. 10 indexed citations

17.

Restrepo, Alejandro, Natalie S. Callander, Darren Postoak, et al.. (2002). Performance of a hybrid central venous catheter utilized for both peripheral blood stem cell harvest and transplant support of patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation. 30(6). 389–395. 6 indexed citations

18.

Gökmen, Erhan, Carlos Bachier, Frank M. Raaphorst, et al.. (2001). Ex Vivo-Expanded Hematopoietic Cell Graft Recipients Exhibit T Cell Repertoire Diversity Similar to That Seen After Conventional Stem Cell Transplants. Journal of Hematotherapy & Stem Cell Research. 10(1). 53–66. 2 indexed citations

19.

Raaphorst, Frank M., Erhan Gökmen, & Judy M. Teale. (1998). Analysis of clonal diversity in mouse immunoglobulin heavy chain genes selected for size of the antigen combining site. Immunological Investigations. 27(6). 355–365. 2 indexed citations

20.

Gökmen, Erhan, et al.. (1969). Der Bürstenschädel. Eine Übersicht über Vorkommen, Röntgenologie, Anatomie, Verlauf und Bedeutung dieses Symptoms. Annals of Hematology. 19(7). 423–437. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact